Rein Therapeutics, Inc. (RNTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Rein Therapeutics, Inc. on September 9, 2025, covering events occurring on September 8, 2025. The filing details the execution of a second tranche under a Pre-Paid Advance Agreement (PPA) previously entered into with YA II PN, Ltd. ("Yorkville") on July 29, 2025.
Key Financial Metrics and Transaction Details
- Transaction Type: Second Pre-Paid Advance under an existing PPA.
- Face Amount: $1.0 million.
- Net Proceeds: $0.95 million (purchased at 95% of face value).
- Interest Rate: 8% annual rate on outstanding balances, subject to increase to 18% upon default.
- Maturity: Due and payable on the 12-month anniversary of issuance.
- Repayment Mechanism: Yorkville may require the issuance of common stock to offset outstanding balances.
- Prior Activity: An initial $1.0 million advance was taken on July 29, 2025. As of this report, $500,000 of that initial advance was offset by the issuance of 479,036 shares at an average price of approximately $1.06 per share.
Material Changes
The primary material change is the increase in the company's debt obligations and cash liquidity resulting from the second $1.0 million advance. The total potential funding available under the PPA is up to $6.0 million over a 12-month period. The filing notes that each additional advance requires the consent of Yorkville.
Outlook, Risks, and Contingencies
- Dilution Risk: The agreement allows Yorkville to demand the issuance of common stock to repay advances, which may result in significant dilution to existing shareholders.
- Default Risk: The interest rate escalates to 18% annually upon the occurrence of events of default.
- Liquidity: The transaction provides immediate liquidity of $0.95 million to the company.
- Regulatory Status: The securities were sold in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933; no underwriter was involved.
Investor Verification Checklist
- Verify the total outstanding balance of Pre-Paid Advances as of the current date.
- Review the specific "events of default" defined in the Pre-Paid Advance Agreement (Exhibit 10.1) that could trigger the 18% interest rate.
- Monitor future filings for any additional stock issuances to Yorkville used to offset debt.
- Confirm the remaining availability of the $6.0 million credit facility under the PPA.